DP
SMMT icon

Diadema Partners’s Summit Therapeutics SMMT Stock Holding History

Diadema Partners’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$874K Buy
+60,000
New +$1.06M 0.11% 109
2025
Q3 		– Sell
-932
Closed -$22.6K – 162
2025
Q2 		$19.8K Buy
+932
New +$21.3K 0.01% 93

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Diadema Partners's SMMT Position: Q2 2026 in Review

Diadema Partners opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 60,000 shares worth $874K. The stake represents 0.11% of the portfolio and ranks #109 among its holdings. This is a return to the name: Diadema Partners previously reported a position in SMMT as recently as Q2 2025.

Diadema Partners first reported a position in SMMT in Q2 2025 and has held it in 2 quarters since. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Diadema Partners held 60,000 shares of Summit Therapeutics worth $874K as of Q2 2026.
  • Summit Therapeutics was a new Diadema Partners position in Q2 2026.
  • Summit Therapeutics made up 0.11% of Diadema Partners's portfolio in Q2 2026, its #109 holding.
  • Diadema Partners first reported a position in Summit Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.